The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.
 
Juanita Suzanne Lopez
Consulting or Advisory Role - Genmab; Novartis
Research Funding - Basilea (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Basilea; Roche/Genentech
 
Manuel SelviMiralles
No Relationships to Disclose
 
Malaka Ameratunga
No Relationships to Disclose
 
Anna Minchom
No Relationships to Disclose
 
Javier Pascual
No Relationships to Disclose
 
Udai Banerji
Employment - Institute of Cancer Research
Honoraria - Astellas Pharma; Lilly
Consulting or Advisory Role - Novartis; Phoenix Solutions
Research Funding - AstraZeneca (Inst); BTG (Inst); Chugai Pharma (Inst); Onyx (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Sierra Oncology
 
Hannah Bye
No Relationships to Disclose
 
Florence I. Raynaud
Patents, Royalties, Other Intellectual Property - Boston Pharmaceuticals; Boston Pharmaceuticals (Inst); BTG; BTG (Inst); Janssen; Janssen (Inst)
 
Karen E Swales
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Pharmaceuticals (Inst); Menarini (Inst); Sierra Oncology (Inst); Verastem (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Employees of The Institute of Cancer Research are subject to a Rewards to Inventors Scheme which may reward contributors to a programme that is subsequently licensed.
 
Jason Malia
No Relationships to Disclose
 
Michael Hubank
Honoraria - Lilly; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Guardant Health
Research Funding - Celgene; Celgene (Inst)
 
Isaac Garcia-Murillas
No Relationships to Disclose
 
Mona Parmar
No Relationships to Disclose
 
Sarah Emily Ward
No Relationships to Disclose
 
Laura Finneran
No Relationships to Disclose
 
Emma Hall
Research Funding - Accuray (Inst); Alliance Pharma (Inst); AstraZeneca (Inst); Bayer Health (Inst); Kyowa Hakko Kirin (Inst); Merck Sharp & Dome (Inst); Sanofi/Aventis (Inst)
 
Alison Joanne Turner
No Relationships to Disclose
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Timothy A Yap
Honoraria - AstraZeneca; Pfizer
Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; Ignyta; Janssen; Merck; Pfizer; Roche; Seagen; Tesaro; Vertex
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca; Bayer; Constellation Pharmaceuticals; Jounce Therapeutics; Kyowa Hakko Kirin; Lilly; Pfizer; Seagen; Tesaro; Vertex
Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center holds the intellectual property rights to IACS-010759 and its designated use. (Inst)
Travel, Accommodations, Expenses - EMD Serono; Pfizer; Tesaro
 
Nicholas C. Turner
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Tesaro
Research Funding - AstraZeneca (Inst); Bio-Rad (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Pfizer (Inst); Roche (Inst)